Bone Marrow Transplant Induction and Conditioning in One
Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. The SIERRA trial completed patient enrollment in the third quarter of 2021. View highlights of Key Opinion Leaders discussing Iomab-B:
Actinium Pharmaceuticals' drug development pipeline features Iomab-B, which completed enrollment of its pivotal Phase 3 clinical trial, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies that is being studied in an NIH funded clinical study and Actimab-A, which is being studied in two combination trials for relapsed/refractory AML. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.
